For the fiscal year ending March 2026, consolidated net sales were JPY 284,492 million (down 1.2% YoY), operating income was JPY 6,779 million (down 9.1% YoY), and net income attributable to owners of parent was JPY 3,200 million (down 34.5% YoY).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2664","jir_company_name":"Kawachi Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-04-28","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/2664-20260428-01.pdf","jir_short_summary":"For the fiscal year ending March 2026, consolidated net sales were JPY 284,492 million (down 1.2% YoY), operating income was JPY 6,779 million (down 9.1% YoY), and net income attributable to owners of parent was JPY 3,200 million (down 34.5% YoY).","jir_summary":"### Overview of Financial Results\nFor the fiscal year ending March 2026, consolidated net sales were JPY 284,492 million (down 1.2% YoY), operating income was JPY 6,779 million (down 9.1% YoY), ordinary income was JPY 7,897 million (down 5.3% YoY), and net income attributable to owners of parent was JPY 3,200 million (down 34.5% YoY). The primary cause of decreased profits was the recording of impairment losses. Sales declined slightly across pharmaceuticals, cosmetics, general merchandise, and general food divisions. The number of stores reached 386 (160 with pharmacies), including 6 new store openings and 4 new pharmacy attachments. The equity ratio stood at 58.0%, up 0.7 points from the previous period, maintaining sound financial health.\n\n### Dividends and Future Outlook\nThe year-end dividend for the fiscal year ending June 2026 is planned at JPY 100, consisting of a regular dividend of JPY 80 plus a 65th anniversary commemorative dividend of JPY 20. For the next fiscal year ending March 2027, an interim dividend will be introduced, with an annual dividend forecasted at JPY 100 (interim JPY 50, year-end JPY 50). Earnings guidance for fiscal year March 2027 anticipates net sales of JPY 285 billion, operating income of JPY 5.1 billion, ordinary income of JPY 6.0 billion, and net income attributable to owners of parent of JPY 3.0 billion. The company plans to respond to changes in the business environment by promoting systemization and mechanization and strengthening specialization.","jir_financial_highlights":"Net Sales: JPY 284,492 million (Down 1.2% YoY)\nOperating Income: JPY 6,779 million (Down 9.1% YoY)\nOrdinary Income: JPY 7,897 million (Down 5.3% YoY)\nNet Income Attributable to Owners of Parent: JPY 3,200 million (Down 34.5% YoY)\nEquity Ratio: 58.0% (Up 0.7 points from previous period)\nAnnual Dividend (Fiscal Year-End): JPY 100 (Regular Dividend JPY 80 + 65th Anniversary Commemorative Dividend JPY 20) (Increased from JPY 80 in the previous period)\nNumber of Issued Shares (Fiscal Year-End): 24,583,420 shares (Same as previous period)\nNumber of Stores: 386 stores (160 stores with pharmacy) (6 new store openings, 4 with associated pharmacies)","jir_category":"","jir_hashtags":"#KawachiPharmaceutical, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales: JPY 284,492 million (Down 1.2% YoY)\nNet Income Attributable to Owners of Parent: JPY 3,200 million (Down 34.5% YoY)\nAnnual Dividend: JPY 100 (Regular Dividend JPY 80 + 65th Anniversary Commemorative Dividend JPY 20)","jir_meta_title":"\u3010Kawachi Pharmaceutical\u3011Fiscal Year Ending March 2026 Financial Results | Net Sales JPY 284.5 Billion (Down 1.2% YoY)","jir_meta_description":"Announcement of Kawachi Pharmaceutical\u2019s consolidated financial results for fiscal year ending March 2026. Net sales of JPY 284,492 million (down 1.2% YoY), operating income of JPY 6,779 million (down 9.1% YoY), net income of JPY 3,200 million (down 34.5% YoY). Year-end dividend planned at JPY 100.","jir_og_title":"\u3010Kawachi Pharmaceutical\u3011Fiscal Year Ending March 2026 Financial Results | Net Sales JPY 284.5 Billion (Down 1.2% YoY)","jir_og_description":"Kawachi Pharmaceutical\u2019s financial summary for fiscal year ending March 2026. Net sales JPY 284,492 million, operating income JPY 6,779 million, net income JPY 3,200 million. Dividend planned at JPY 100.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend (Millions of JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending March 2022\\\",\\\"Fiscal Year Ending March 2023\\\",\\\"Fiscal Year Ending March 2024\\\",\\\"Fiscal Year Ending March 2025\\\",\\\"Fiscal Year Ending March 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[286881,286881,\u4e0d\u660e,287816,284492],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend (Millions of JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending March 2022\\\",\\\"Fiscal Year Ending March 2023\\\",\\\"Fiscal Year Ending March 2024\\\",\\\"Fiscal Year Ending March 2025\\\",\\\"Fiscal Year Ending March 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[\u4e0d\u660e,\u4e0d\u660e,\u4e0d\u660e,7461,6779],\\\"borderColor\\\":\\\"#8e5ea2\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (Millions of JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending March 2022\\\",\\\"Fiscal Year Ending March 2023\\\",\\\"Fiscal Year Ending March 2024\\\",\\\"Fiscal Year Ending March 2025\\\",\\\"Fiscal Year Ending March 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[\u4e0d\u660e,\u4e0d\u660e,\u4e0d\u660e,4884,3200],\\\"borderColor\\\":\\\"#3cba9f\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment Revenue Composition Ratio for Fiscal Year Ending March 2026\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceuticals\\\",\\\"Cosmetics\\\",\\\"General Merchandise\\\",\\\"General Food\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales Composition Ratio\\\",\\\"data\\\":[18.1,8.2,27.3,46.4],\\\"backgroundColor\\\":[\\\"#ff6384\\\",\\\"#36a2eb\\\",\\\"#cc65fe\\\",\\\"#ffce56\\\"]}]},\\\"options\\\":{\\\"responsive\\\":true}}\"}, {\"jir_chart_id\": \"dividend_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Annual Dividend Trend (JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending March 2025\\\",\\\"Fiscal Year Ending March 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Annual Dividend\\\",\\\"data\\\":[80,100],\\\"backgroundColor\\\":\\\"#ff9f40\\\"}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":false}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":16960,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-43679","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n